Yumei Ye

5.0k total citations
101 papers, 4.0k citations indexed

About

Yumei Ye is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Yumei Ye has authored 101 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 28 papers in Cardiology and Cardiovascular Medicine and 26 papers in Pathology and Forensic Medicine. Recurrent topics in Yumei Ye's work include Cardiac Ischemia and Reperfusion (23 papers), Diabetes Treatment and Management (16 papers) and Cardiac Imaging and Diagnostics (12 papers). Yumei Ye is often cited by papers focused on Cardiac Ischemia and Reperfusion (23 papers), Diabetes Treatment and Management (16 papers) and Cardiac Imaging and Diagnostics (12 papers). Yumei Ye collaborates with scholars based in United States, China and Sweden. Yumei Ye's co-authors include Yochai Birnbaum, J. R. Perez‐Polo, Mandeep Bajaj, Yu Lin, Jinqiao Qian, Barry F. Uretsky, Ming-He Huang, Sven Nylander, Kyle T. Keyes and Manjyot K. Nanhwan and has published in prestigious journals such as Circulation, Bioinformatics and The Journal of Immunology.

In The Last Decade

Yumei Ye

95 papers receiving 4.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yumei Ye United States 32 1.6k 1.0k 811 749 649 101 4.0k
Patrizia Ferroni Italy 41 1.2k 0.7× 1.1k 1.0× 734 0.9× 393 0.5× 386 0.6× 218 5.5k
Masanori Asakura Japan 41 2.6k 1.6× 2.5k 2.4× 1.3k 1.6× 483 0.6× 586 0.9× 216 6.5k
Shin Watanabe Japan 33 1.3k 0.8× 924 0.9× 1.7k 2.0× 1.7k 2.3× 343 0.5× 134 4.2k
Ruiyan Zhang China 36 1.2k 0.7× 1.9k 1.8× 1.3k 1.6× 709 0.9× 236 0.4× 243 4.6k
Rini de Crom Netherlands 34 1.3k 0.8× 1.3k 1.2× 1.2k 1.5× 387 0.5× 251 0.4× 68 4.0k
Toru Miyoshi Japan 37 895 0.6× 2.2k 2.1× 1.2k 1.4× 718 1.0× 248 0.4× 233 4.4k
Ferdinand H. Bahlmann Germany 30 2.4k 1.5× 960 0.9× 1.2k 1.4× 472 0.6× 175 0.3× 59 5.1k
Toshiaki Mano Japan 36 1.4k 0.8× 2.5k 2.5× 981 1.2× 424 0.6× 186 0.3× 260 4.9k
Susana Ravassa Spain 34 1.2k 0.7× 2.0k 2.0× 628 0.8× 425 0.6× 173 0.3× 90 3.4k

Countries citing papers authored by Yumei Ye

Since Specialization
Citations

This map shows the geographic impact of Yumei Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yumei Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yumei Ye more than expected).

Fields of papers citing papers by Yumei Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yumei Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yumei Ye. The network helps show where Yumei Ye may publish in the future.

Co-authorship network of co-authors of Yumei Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Yumei Ye. A scholar is included among the top collaborators of Yumei Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yumei Ye. Yumei Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ye, Yumei, et al.. (2025). Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study. Therapeutic Advances in Medical Oncology. 17. 22828964–22828964.
2.
Yuan, Chenwei, Yaqian Xu, Liheng Zhou, et al.. (2024). Value of CDR1-AS as a predictive and prognostic biomarker for patients with breast cancer receiving neoadjuvant chemotherapy in a prospective Chinese cohort. European journal of medical research. 29(1). 454–454. 1 indexed citations
3.
Ye, Yumei, Qiang Yang, Jingang Zhang, Songhe Meng, & Jun Wang. (2023). A dynamic data driven reliability prognosis method for structural digital twin and experimental validation. Reliability Engineering & System Safety. 240. 109543–109543. 23 indexed citations
4.
Ye, Yumei, Jingang Zhang, Qiang Yang, Songhe Meng, & Jun Wang. (2023). Complete ensemble empirical mode decomposition with adaptive noise for dynamic response reconstruction of spacecraft structures under random vibration. Insight - Non-Destructive Testing and Condition Monitoring. 65(12). 666–674. 1 indexed citations
5.
Wu, Yifan, Yaohui Wang, Chang He, et al.. (2023). Precise diagnosis of breast phyllodes tumors using Raman spectroscopy: Biochemical fingerprint, tumor metabolism and possible mechanism. Analytica Chimica Acta. 1283. 341897–341897. 8 indexed citations
6.
Birnbaum, Yochai, Huan Chen, Leif Carlsson, et al.. (2022). Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury. Cardiovascular Drugs and Therapy. 37(4). 625–646. 6 indexed citations
7.
Ye, Yumei, et al.. (2019). The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury. Cardiovascular Drugs and Therapy. 33(4). 489–498. 26 indexed citations
8.
Birnbaum, Yochai, Dat Q. Tran, Mandeep Bajaj, & Yumei Ye. (2019). DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Research in Cardiology. 114(5). 35–35. 58 indexed citations
9.
Jia, Xiaoming, Mahboob Alam, Yumei Ye, Mandeep Bajaj, & Yochai Birnbaum. (2018). GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovascular Drugs and Therapy. 32(1). 65–72. 25 indexed citations
10.
Jia, Xiaoming, et al.. (2018). SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. Current Diabetes Reports. 18(9). 63–63. 12 indexed citations
11.
Yang, Wei, et al.. (2017). The extract of Lycium barbarum L. improves the behavior of rats with premature ovarian by regulating related genes. Biomedical Research-tokyo. 28(13). 5874–5879.
12.
Ye, Yumei, Mandeep Bajaj, & Yochai Birnbaum. (2017). DPP4 INHIBITION BY LINAGLIPTIN PREVENTS CARDIAC DYSFUNCTION AND INFLAMMATION BY TARGETING THE NLRP3/ASC INFLAMMASOME. Journal of the American College of Cardiology. 69(11). 199–199. 1 indexed citations
13.
14.
Qian, Jinqiao, Hongmei Chen, Yochai Birnbaum, et al.. (2016). Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. Cardiovascular Drugs and Therapy. 30(2). 129–141. 12 indexed citations
15.
Birnbaum, Yochai, et al.. (2016). Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovascular Drugs and Therapy. 30(6). 539–550. 43 indexed citations
16.
Birnbaum, Yochai, Manjyot K. Nanhwan, Shukuan Ling, et al.. (2014). PTEN Upregulation May Explain the Development of Insulin Resistance and Type 2 Diabetes with High Dose Statins. Cardiovascular Drugs and Therapy. 28(5). 447–457. 26 indexed citations
17.
Qian, Jinqiao, Kyle T. Keyes, Bo Long, Guanglin Chen, & Yumei Ye. (2011). Impact of HMG‐CoA reductase inhibition on oxidant‐induced injury in human retinal pigment epithelium cells. Journal of Cellular Biochemistry. 112(9). 2480–2489. 22 indexed citations
18.
19.
Ye, Yumei, et al.. (2008). The role of eNOS, iNOS, and NF-κB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. American Journal of Physiology-Heart and Circulatory Physiology. 295(1). H343–H351. 72 indexed citations
20.
Ye, Yumei, Yu Lin, Regino Perez‐Polo, et al.. (2007). The Cardioprotective Effect of a Statin and Cilostazol Combination: Relationship to Akt and Endothelial Nitric Oxide Synthase Activation. Cardiovascular Drugs and Therapy. 21(5). 321–330. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrizia Ferroni Breakdown of academic impact, for papers by Masanori Asakura Breakdown of academic impact, for papers by Shin Watanabe Breakdown of academic impact, for papers by Ruiyan Zhang Breakdown of academic impact, for papers by Rini de Crom Breakdown of academic impact, for papers by Toru Miyoshi Breakdown of academic impact, for papers by Ferdinand H. Bahlmann Breakdown of academic impact, for papers by Toshiaki Mano Breakdown of academic impact, for papers by Susana Ravassa
Rankless by CCL
2026